StockNews.AI
POAI
StockNews.AI
181 days

Predictive Oncology Closes Registered Direct Offering

1. Predictive Oncology raised $545,004 from a stock offering at $1.50 each. 2. Proceeds will support working capital and corporate purposes. 3. The company’s AI platform offers 92% accuracy in drug response prediction. 4. Predictive Oncology holds a comprehensive biobank of over 150,000 tumor samples. 5. Offering was conducted under SEC's effective 'shelf' registration statement.

6m saved
Insight
Article

FAQ

Why Neutral?

Recent capital raise is standard for funding but may dilute shares. Similar offerings often lead to temporary market reactions.

How important is it?

The article highlights a significant funding event for POAI, influencing short-term price actions but does not indicate major operational changes.

Why Short Term?

Stock price may be affected short-term due to immediate dilution concerns. However, long-term growth relies on successful application of funds.

Related Companies

NASDAQ: POAI
February 19, 2025 17:20 ET  | Source: Predictive Oncology Inc. PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to the Company from the offering were approximately $545,004 before deducting placement agent fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The common stock described above were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333- 279123) that was declared effective by the Securities and Exchange Commission (the “SEC”) on May 21, 2024. The offering of the shares of common stock was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the registered direct offering was filed with the SEC on February 19, 2025. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, New York 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Predictive Oncology Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The Company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the Company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA laboratory facility. Predictive Oncology is headquartered in Pittsburgh, PA. Investor Relations Contact: Tim McCarthyLifeSci Advisors, LLCtim@lifesciadvisors.com Forward-Looking Statements: Certain matters discussed in this release contain forward-looking statements, including, without limitation, the anticipated use of proceeds from offering. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.

Related News